ReviewThe Lancet regional health. Europe2025
Control of HIV across the WHO European region: progress and remaining challenges.
Review in The Lancet regional health. Europe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Perinatal HIV in Europe: Clinical Advances and Psychosocial Challenges-A Scoping Review.Tropical medicine and infectious disease · 2026Review
- Factors Associated with Virological Non-Suppression Among People Living with HIV Receiving Antiretroviral Therapy in Kazakhstan: A National Registry-Based Study.Tropical medicine and infectious disease · 2026Article
- Missed Opportunities for HIV Testing in Hospitalised Adults in Türkiye: Indicator Conditions and Testing Coverage in a National Multicentre Point-Prevalence Survey (HIV-ICs-TR).Scientific reports · 2026Article
- Application of machine-learning algorithms to identify the key determinants of risk for HIV, hepatitis C and hepatitis B in primary care settings.BMC infectious diseases · 2026Article
- Role of Community Associations in HIV, HBV and HCV Screening and Support for Migrant Populations in France: Results of the DéPAC Study.Infectious diseases and therapy · 2026Article
- Estimating the HIV PrEP care continuum among gay, bisexual and other men who have sex with men in Amsterdam and the Netherlands.AIDS (London, England) · 2026Article
- Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort.Journal of the International AIDS Society · 2026Observational
- Pre-conflict prescription patterns and virological effectiveness of combination antiretroviral therapy (cART) in HIV-1 patients in Tigray, Ethiopia.AIDS research and therapy · 2026Article
- Evaluating HIV-1 Transmitted Drug Resistance and Clustering in Newly Diagnosed Patients in Romania (2019-2022).Viruses · 2026Article
- Human Immunodeficiency Virus Infection in Romania Versus Europe: An Epidemiological and Public Health Perspective, 2024 Update.Infectious disease reports · 2026Article
- Feasibility and reliability of decentralized HIV-1 viral load monitoring on self-sampled blood.PloS one · 2026Article
- Stakeholders' perspectives on HIV prevention in the Czech Republic: a qualitative study.Frontiers in public health · 2026Article
- Community-Based Rapid Testing for HIV in Europe and Central Asia: A Narrative Review of Models, Effectiveness, and Implementation Challenges.Infection and drug resistance · 2026Review
- Article
- Avoiding the cost of complacency: barriers and solutions to ending the HIV epidemic in Europe.Frontiers in public health · 2026Article
- Using Latent Profile Analysis to Identify Stigma Typologies Among a Sample of Women Living with HIV and Who Inject Drugs in Ukraine.AIDS and behavior · 2026Article
- Pre-exposure prophylaxis against HIV infection among male population under perceived risk of sexually transmitted infections in Vojvodina, Serbia: a cross-sectional study on knowledge and attitudes.Frontiers in reproductive health · 2026Article
- Refractory Dermatophytosis and Oral Hairy Leukoplakia as Sentinel Manifestations of Advanced HIV Infection.Cureus · 2025Article
- Readability and information quality of LLM-Generated HIV content: a methodological content evaluation.BMC infectious diseases · 2025Article
- Opt-in and opt-out strategies for HIV testing.The Lancet regional health. Europe · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Despite the ambitious global goal to control HIV transmissions by 2030, more than 30% of people with HIV from the WHO European Region show persistent transmissible levels of the virus. Successful introduction of oral pre-exposure prophylaxis (PrEP) has led to significant decreases in new HIV transmissions in some areas of Europe, particularly among men who have sex with men. However, the limited PrEP access or lack of state funding in many European countries underlines the need to increase efforts to make PrEP consistently and equitably available for all individuals in need. The success of modern antiretroviral therapy (ART) is evident throughout the WHO European region, with more than 90% of treated individuals with viral suppression. Remaining barriers to control HIV include disparities in access to testing facilities such as community-based centers, persistently high levels of late diagnosis, delayed linkage to care especially for undocumented migrant populations, and inequalities in access to treatment. Retention in care and maintenance of viral suppression are additional challenges. The ongoing war in Ukraine is causing service disruption for people with HIV. Combating HIV associated stigma and discrimination, particularly in Eastern Europe and Central Asia, seems paramount in removing barriers to testing; new testing strategies, such as emergency room opt-out testing, could enable earlier diagnosis of HIV in transmission groups that have been difficult to reach. This review summarizes the barriers, opportunities, and pathways towards improvement of the HIV response in the WHO European region.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.